Edmp Inc. increased its position in Abbott Laboratories (NYSE:ABT) by 0.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 22,256 shares of the healthcare product maker’s stock after acquiring an additional 35 shares during the period. Edmp Inc.’s holdings in Abbott Laboratories were worth $1,082,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Waldron LP lifted its stake in Abbott Laboratories by 41.0% during the 1st quarter. Waldron LP now owns 10,042 shares of the healthcare product maker’s stock valued at $442,000 after acquiring an additional 2,922 shares during the period. GW Henssler & Associates Ltd. boosted its holdings in shares of Abbott Laboratories by 9.2% during the 1st quarter. GW Henssler & Associates Ltd. now owns 232,942 shares of the healthcare product maker’s stock valued at $10,345,000 after acquiring an additional 19,592 shares during the last quarter. Sigma Planning Corp boosted its holdings in shares of Abbott Laboratories by 8.6% during the 1st quarter. Sigma Planning Corp now owns 30,860 shares of the healthcare product maker’s stock valued at $1,370,000 after acquiring an additional 2,435 shares during the last quarter. IFC Holdings Incorporated FL boosted its holdings in shares of Abbott Laboratories by 44.7% during the 1st quarter. IFC Holdings Incorporated FL now owns 21,193 shares of the healthcare product maker’s stock valued at $945,000 after acquiring an additional 6,545 shares during the last quarter. Finally, Reik & CO. LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $215,000. Institutional investors own 71.50% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/03/abbott-laboratories-abt-position-boosted-by-edmp-inc.html.

A number of analysts have recently commented on the stock. TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b” rating in a research note on Monday, July 3rd. Jefferies Group LLC restated a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a research report on Friday, June 16th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $53.00 price objective on the stock in a research report on Wednesday, June 14th. Guggenheim started coverage on shares of Abbott Laboratories in a report on Thursday, June 29th. They issued a “buy” rating and a $58.00 target price on the stock. Finally, BTIG Research started coverage on shares of Abbott Laboratories in a report on Wednesday, June 21st. They issued a “buy” rating and a $56.00 target price on the stock. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Abbott Laboratories presently has a consensus rating of “Buy” and a consensus price target of $54.00.

In other news, insider Stephen R. Fussell sold 196,550 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $49.50, for a total value of $9,729,225.00. Following the sale, the insider now directly owns 221,488 shares of the company’s stock, valued at approximately $10,963,656. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sharon J. Bracken sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total transaction of $98,320.00. Following the completion of the sale, the insider now directly owns 28,806 shares in the company, valued at $1,416,102.96. The disclosure for this sale can be found here. Insiders sold 333,310 shares of company stock valued at $16,857,255 in the last three months. 0.76% of the stock is currently owned by insiders.

Shares of Abbott Laboratories (NYSE:ABT) traded up 0.28% during mid-day trading on Tuesday, reaching $53.83. The company’s stock had a trading volume of 2,583,694 shares. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $54.80. The firm has a market cap of $93.53 billion, a P/E ratio of 75.39 and a beta of 1.06. The firm’s 50-day moving average price is $51.11 and its 200 day moving average price is $47.53.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.60 by $0.02. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. During the same period in the previous year, the company posted $0.55 earnings per share. The business’s revenue was up 24.5% on a year-over-year basis. On average, analysts expect that Abbott Laboratories will post $2.49 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be issued a $0.265 dividend. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.97%. The ex-dividend date is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio is currently 149.30%.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Stock Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related stocks with our FREE daily email newsletter.